Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.

Ho-Cheol Kim, Kyung-Wook Jo, Young Ju Jung, Bin Yoo, Chang-Keun Lee, Yong-Gil Kim, Suk-Kyun Yang, Jeong-Sik Byeon, Kyung-Jo Kim, Byong Duk Ye, Tae Sun Shim
{"title":"Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.","authors":"Ho-Cheol Kim,&nbsp;Kyung-Wook Jo,&nbsp;Young Ju Jung,&nbsp;Bin Yoo,&nbsp;Chang-Keun Lee,&nbsp;Yong-Gil Kim,&nbsp;Suk-Kyun Yang,&nbsp;Jeong-Sik Byeon,&nbsp;Kyung-Jo Kim,&nbsp;Byong Duk Ye,&nbsp;Tae Sun Shim","doi":"10.3109/00365548.2014.938691","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Reactivation of latent tuberculosis infection (LTBI) is an important complication in patients treated with tumor necrosis factor-alpha (TNF-α) blocking agents. However, the best method for LTBI detection before initiation of anti-TNF therapy remains to be determined.</p><p><strong>Methods: </strong>From January 2010 to August 2013, anti-TNF therapy was initiated in 426 patients with immune-mediated inflammatory diseases (IMIDs). Tuberculin skin test (TST) and Quantiferon-TB Gold In Tube (QFT-GIT) assay were performed before starting anti-TNF treatment. LTBI was defined as a positive TST (induration ≥ 10 mm) or as a positive QFT-GIT result. Patients were followed up until December 2013.</p><p><strong>Results: </strong>The positive TST and QFT-GIT rates were 22.3% (95/426) and 16.0% (68/426), respectively, yielding a total of 27.0% (115/426) of positive LTBI results. LTBI treatment was initiated in 25.1% (107/426) and was completed in 100% (107/107) of patients. During a median 294 days of follow-up, active TB occurred in 1.4% (6/426) of the patients with negative TST and QFT-GIT results at baseline.</p><p><strong>Conclusion: </strong>The either test positive strategy, using both TST and QFT-GIT assay, is acceptable for LTBI screening before commencing anti-TNF therapy in patients with IMIDs.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":"46 11","pages":"763-9"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.938691","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/00365548.2014.938691","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/9/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 28

Abstract

Background: Reactivation of latent tuberculosis infection (LTBI) is an important complication in patients treated with tumor necrosis factor-alpha (TNF-α) blocking agents. However, the best method for LTBI detection before initiation of anti-TNF therapy remains to be determined.

Methods: From January 2010 to August 2013, anti-TNF therapy was initiated in 426 patients with immune-mediated inflammatory diseases (IMIDs). Tuberculin skin test (TST) and Quantiferon-TB Gold In Tube (QFT-GIT) assay were performed before starting anti-TNF treatment. LTBI was defined as a positive TST (induration ≥ 10 mm) or as a positive QFT-GIT result. Patients were followed up until December 2013.

Results: The positive TST and QFT-GIT rates were 22.3% (95/426) and 16.0% (68/426), respectively, yielding a total of 27.0% (115/426) of positive LTBI results. LTBI treatment was initiated in 25.1% (107/426) and was completed in 100% (107/107) of patients. During a median 294 days of follow-up, active TB occurred in 1.4% (6/426) of the patients with negative TST and QFT-GIT results at baseline.

Conclusion: The either test positive strategy, using both TST and QFT-GIT assay, is acceptable for LTBI screening before commencing anti-TNF therapy in patients with IMIDs.

结核菌素皮试和QuantiFERON-TB金管试验在抗肿瘤坏死因子治疗开始前诊断潜伏性结核感染。
背景:潜伏性结核感染(LTBI)再激活是肿瘤坏死因子-α (TNF-α)阻滞剂治疗患者的一个重要并发症。然而,在抗tnf治疗开始前检测LTBI的最佳方法仍有待确定。方法:2010年1月至2013年8月,对426例免疫介导性炎症性疾病(IMIDs)患者进行抗tnf治疗。在开始抗tnf治疗前进行结核菌素皮肤试验(TST)和Quantiferon-TB金管(QFT-GIT)试验。LTBI被定义为TST阳性(硬化≥10 mm)或QFT-GIT阳性结果。患者随访至2013年12月。结果:TST阳性率为22.3% (95/426),QFT-GIT阳性率为16.0% (68/426),LTBI阳性率为27.0%(115/426)。开始LTBI治疗的患者占25.1%(107/426),完成LTBI治疗的患者占100%(107/107)。在中位294天的随访期间,基线TST和QFT-GIT结果阴性的患者中有1.4%(6/426)发生活动性结核病。结论:在IMIDs患者开始抗tnf治疗前,使用TST和QFT-GIT检测两种检测阳性策略均可用于LTBI筛查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信